Market Newsdesk

• Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases and Immunology at the UMass Chan Medical School
• Inflammasome ASC Inhibitor IC 100 is a differentiated humanized IgG4 monoclonal antibody designed to inhibit formation of multiple types of inflammasomes and disrupt the structure and function of ASC Specks to control initiation and perpetuation of damaging inflammation associated with numerous diseases

WESTON, Fla., April 24, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that internationally recognized authority in the field of innate immunity, Dr. Douglas Golenbock, has joined ZyVersa’s Inflammatory Disease Scientific Advisory Board.

Dr. Golenbock is a physician-scientist who has spent much of his career developing therapeutic interventions for important human diseases. He has made substantial contributions to the investigation of innate immune mechanisms in human cells. His major interests are in the mechanisms of inflammation, such as NLRP3-related inflammation in Alzheimer’s disease, the role of the innate immune response in gonococcal infections, nucleic acid recognition in both bacterial infections and malaria, and epigenetics related to malaria infection. His laboratory was one of the first in the world to study Toll receptors.

Dr. Golenbock has nearly 300 peer-reviewed publications, many in high-impact journals, and over 81,000 citations. He has received continuous funding from the NIH for over 30 years and has been a recipient of an NIH MERIT Award. He is an elected member of the Brazilian Academy of Sciences and has received the Sheldon E. Greisman Award from the International Endotoxin & Innate Immune Society, an award that is given to an investigator who has made substantial and original contributions which have led to an increased understanding of the interactions between microorganisms and innate immunity. Dr. Golenbock has been an organizer and chair of the international Toll meetings that have become the major specialty scientific meeting in his field, and he is a founding and current co-chair of the annual Innate Immunity Day scientific symposium on the campus of UMass Chan Medical School.

Dr. Golenbock earned his medical degree from the University of Michigan Medical School in Ann Arbor, Michigan. He completed his Internal Medicine internship and residency at George Washington University Hospital in Washington, DC, and his fellowship in Infectious Diseases at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin. He also completed a postdoctoral research fellowship in biochemistry in the laboratory of Christian R.H. Raetz at the University of Wisconsin and Merck Research Laboratories in New Jersey.

“We are honored that Dr. Golenbock, an established leader in the field of innate immunity, specifically in the field of Toll-like receptors in infection and inflammation, is joining our Inflammatory Disease Scientific Advisory Board,” stated Stephen C. Glover, ZyVersa’s Co-founder, Chief Executive Officer, and Chairman. “We look forward to his invaluable insights and contributions as we advance our clinical development program for Inflammasome ASC Inhibitor IC 100.”

Dr. Golenbock joins ZyVersa’s current team of prominent Scientific Advisors:

• Daniel G. Baker, MD: Former Vice President, Immunology Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson
• Miguel S. Barbosa, PhD: Former Global Head and Vice President of Immunology Research and External Innovation at Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson
• William F. Bennett, PhD: Principal, Bioscope Associates; formerly Genentech, Sensus Corporation, and Cor Therapeutics
• Helen Bramlett, PhD: Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine, and The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
• W. Dalton Dietrich, III, PhD: Kinetic Concepts Distinguished Chair in Neurosurgery, and Scientific Director at The Miami Project to Cure Paralysis, the University of Miami Miller School of Medicine; Senior Associate Dean for Discovery Science and Co-Director of the Institute for Neural Engineering, University of Miami Miller School of Medicine; Professor, Neurological Surgery, Neurology, Biomedical Engineering, and Cell Biology, University of Miami Miller School of Medicine
• Juan Pablo de Rivero Vaccari, PhD: Associate Professor, Department of Neurological Surgery and The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine; Distinguished Faculty Member of The Center for Cognitive Neuroscience and Aging, University of Miami Miller School of Medicine
• Douglas H. Farrar: CEO, Flatirons Biotech, Inc.; former Cofounder and Chief Technical Officer, Coherus Biosciences
• Alan Herman, PhD: Chairman Emeritus, former Chief Scientific Officer at Coherus BioSciences; formerly Genentech, Amgen, and Merck
• Robert W. Keane, PhD: Professor, Physiology and Biophysics, Neurological Surgery and Microbiology, and Immunology, University of Miami Miller School of Medicine; The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine

About Inflammasome ASC Inhibitor IC 100

IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 attenuates both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, and Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1β early in the inflammatory cascade. IC 100 also binds to ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1β and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 developed to ameliorate renal lipid accumulation that damages the kidneys’ filtration system in patients with glomerular kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.

Corporate and IR Contact

Karen Cashmere
Chief Commercial Officer
[email protected]
786-251-9641                

Media Contacts

Casey McDonald
[email protected]
646-577-8520

Dave Schemelia
[email protected]
609-468-9325

                

WARSAW, Ind., April 24, 2023 (GLOBE NEWSWIRE) — Lake City Bank opened its 53rd office in the 16 Tech Innovation District on April 10. The new branch is located inside the AMP food and event hall at 1220 Waterway Blvd, Suite #A140, Indianapolis, IN 46202. A grand opening ribbon cutting celebration will take place at a later date.

The full-service office is open 9 a.m. to 5 p.m. Monday through Friday and is uniquely positioned to serve businesses on the Northwest side of downtown and consumers frequenting the AMP. The new branch is the bank’s seventh location in the Indianapolis market and second on the Northwest side.

“We’re thrilled to open our newest branch in the Indianapolis market, and in particular, at 16 Tech,” said Stephanie R. Leniski, Senior Vice President, Chief Retail Banking Officer. “Our team looks forward to building banking relationships with the 16 Tech community and the surrounding neighborhoods on Indianapolis’s Northwest side.”

“To see our branch open is the realization of our vision to be a long-term partner to 16 Tech Community Corporation and the Central Indiana Corporate Partnership, whose headquarters are in the 16 Tech Innovation District,” said David M. Findlay, President and Chief Executive Officer. “This branch, in addition to our partnership with the Flanner House, underscores our continued investment to help improve the quality of life of residents on the Northwest side of Indianapolis. Our efforts here represent the latest example of how our community banking model is a catalyst for building stronger communities with collaborative partners.” 

The 16 Tech Innovation District is home to 90 companies and more than 700 people working in the District. Lake City Bank will join the 20 restaurants and retailers in the AMP, which serves as a community hub and is home to local food startups and entrepreneurs, 65% of which are female or minority owned and operated.

“We’re excited to see Lake City Bank’s branch open in the AMP at 16 Tech,” said Emily Krueger, President and Chief Executive Officer of 16 Tech Community Corporation. “Lake City Bank’s early support and creative financing was critical to 16 Tech’s ability to transform the former Indianapolis Water Company building into the HqO innovation hub. Their partnership enabled us to create a vibrant and critical community asset that provides access to entrepreneurship resources as well as the amenities and social spaces where neighbors, district tenants and the community at large can connect and collaborate.”  

Lake City Bank, a $6.4 billion bank headquartered in Warsaw, Indiana, is the sixth largest bank headquartered in the state, and the largest bank 100% invested in Indiana. Lake City Bank operates 53 branch offices in northern and central Indiana, delivering technology-driven solutions in a client-centric way to individuals and businesses. The bank is the single bank subsidiary of Lakeland Financial Corporation (Nasdaq Global Select/LKFN). For more information visit lakecitybank.com.  

About the 16 Tech Innovation District

The 16 Tech Innovation District is a 50-acre community dedicated to world-changing innovation and economic opportunity. Located in the historic Riverside neighborhood of Indianapolis, 16 Tech leverages its proximity to top academic, corporate, and healthcare institutions—and a growing network of spaces, programs, and talent—to foster the cross-industry convergence and collaboration that make world-changing innovation possible. The nonprofit 16 Tech Community Corporation oversees the development of the district and ensures benefits of economic growth, new investment and job creation extend to nearby neighborhoods as well as the city, the region, and the state. More information can be found at www.16tech.com.

Contact

Mary Horan
Director of Marketing and Public Relations
574 371-9280 office
574 377-9150 mobile
[email protected]

WESTLAKE, Texas and PROVO, Utah, April 24, 2023 (GLOBE NEWSWIRE) — Goosehead Insurance, Inc., (NASDAQ: GSHD), a rapidly growing, independent personal lines insurance agency, and Vivint Smart Home, a leading smart home company in the United States, today announced a strategic partnership to innovate and enhance home insurance solutions. The collaboration will simplify the process of protecting and securing homes for consumers and help them to reduce claims and losses. Through the partnership, Goosehead Insurance and Vivint will collaborate to develop innovative new services and offerings that leverage the latest advancements in smart home technology and insurance services. This will allow for more personalized options to help clients find the solutions to meet their unique needs and save on home insurance. As part of the partnership, Goosehead entered into a letter of intent to acquire Vivint Insurance Agency’s current book of business and provide service and support for Vivint’s insurance clients as Vivint shifts its insurance strategy to a partnership model.

“We continue to see increased momentum around the independent insurance distribution model as consumers look for the power of choice and more efficient experiences, and our partnership with Vivint enables us to provide a more comprehensive and integrated home ownership experience,” said Justin Ricketts, Executive Vice President, Technology and Partnerships at Goosehead Insurance. “By combining our industry-leading insurance model with Vivint’s cutting-edge smart home technology, we’re able to offer a truly innovative solution that sets a new standard for the industry and meets the evolving needs of today’s consumer.”

Vivint customers looking for home insurance solutions will now have access to a best-in-class way to shop for and buy personal lines of insurance with the guidance of Goosehead’s expert agents and its Digital Agent Platform, a quoting platform powered by deep, integrated technology that provides consumers with a straightforward and efficient way to find the right home insurance coverage at the best price. Goosehead clients with Vivint systems will also be able to take advantage of additional homeowners insurance discounts and have access to exclusive offers from Vivint to help them further protect and secure their homes.

“We’re excited to partner with Goosehead Insurance as we transition our insurance strategy to a partnership model,” said Rasesh Patel, President, Vivint. “When we entered the insurance space, we knew it would be a natural complement to our smart home offering and that long term, our technology could be used to reduce customer claims and losses while simultaneously improving customer experience. By integrating our smart home technology with Goosehead’s insurance services, we’re able to expand on that vision and together provide an all-in-one solution that gives homeowners greater control over their homes and insurance policies.”

The partnership between Vivint Smart Home and Goosehead Insurance is set to launch in May and will be available to homeowners across the United States.

About Goosehead:

Goosehead (NASDAQ: GSHD) is a rapidly growing and innovative independent personal lines insurance agency that distributes its products and services throughout the United States.   Goosehead was founded on the premise that the consumer should be at the center of our universe and that everything we do should be directed at providing extraordinary value by offering broad product choice and a world-class service experience.   Goosehead represents over 150 insurance companies that underwrite personal lines and small commercial lines risks. For more information, please visit goosehead.com

About Vivint Smart Home:

Vivint, an NRG company, is a leading smart home company in the United States. Vivint delivers an integrated smart home system with in-home consultation, professional installation and support delivered by its Smart Home Pros, as well as 24-7 customer care and monitoring. Dedicated to redefining the home experience with intelligent products and services, Vivint serves more than 1.9 million customers. For more information, visit https://www.vivint.com.

Contacts

Mission North for Goosehead Insurance
Email: [email protected]; [email protected]

Vivint:
Heidi Mendez
Email: [email protected]

 

SYMPAZAN
(clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older

Oral film delivery from SYMPAZAN

^®

delivers clobazam to LGS patients with no crushing, no mixing, no prep work

LAKE FOREST, Ill., April 24, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it is providing educational grant funding for the Lennox-Gastaut Syndrome (LGS) Foundation’s new About LGS Treatments Kits for families coping with LGS. Assertio markets SYMPAZAN^® (clobazam) oral film CIV, approved by the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of seizures associated with LGS in patients aged two years of age or older.

Assertio announced in December that it provided a $100,000 educational grant to the LGS Foundation.

“Assertio is proud to support the LGS community,” said Dan Peisert, President and Chief Executive Officer of Assertio. “Our focus is on working with the LGS Foundation to help raise awareness of LGS and to support development of educational materials that can benefit their community.”

Tracy Dixon-Salazar, Ph.D, Executive Director of the LGS Foundation, said the kits will include information about medications to treat seizures associated with LGS, diet therapy, neuromodulatory treatments, epilepsy surgery, and much more.

“I wish I had a kit like this when my daughter was first diagnosed with LGS over two decades ago,” said Dr. Dixon-Salazar. “Our community has told us that they need more information to help them understand their options for treatment of seizures in LGS. This kit will help do just that.”

Dr. Dixon-Salazar said the Treatment Kits will be provided starting today to any family requesting one. Families impacted by Lennox-Gastaut Syndrome can request an About LGS Treatments Kit on the LGS Foundation’s website.

About LGS Foundation

The Lennox-Gastaut Syndrome (LGS) Foundation is a nonprofit organization dedicated to improving the lives of individuals impacted by LGS through advancing research, awareness, education, and family support. For more information, please visit www.lgsfoundation.org.

About Sympazan

SYMPAZAN is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. SYMPAZAN oral film is berry flavored and offered in 5 mg, 10 mg, and 20 mg dosages to meet a range of LGS patient and caregiver needs.

About Assertio

Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.

INDICATIONS AND USAGE

SYMPAZAN^® (clobazam) oral film, CIV is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

IMPORTANT SAFETY INFORMATION for Sympazan

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

• Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. • The use of benzodiazepines, including SYMPAZAN, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing SYMPAZAN and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. • Abrupt discontinuation or rapid dosage reduction of SYMPAZAN after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue SYMPAZAN.

CONTRAINDICATIONS

SYMPAZAN is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients.

WARNINGS AND PRECAUTIONS

Risks from Concomitant Use with Opioids

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe SYMPAZAN concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use. Advise both patients and caregivers about the risks of respiratory depression and sedation when SYMPAZAN is used with opioids.

Abuse, Misuse, and Addiction

Abuse and misuse of benzodiazepines often (but not always) involves the use of doses greater than the maximum recommended dosage and commonly involves concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death.

Use of SYMPAZAN, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of SYMPAZAN along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of Central Nervous System (CNS) depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.

Dependence and Withdrawal Reactions

Patients at an increased risk of withdrawal reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages and those who have had longer durations of use.

The continued use of benzodiazepines, including SYMPAZAN, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of ONFI after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures). In some cases, benzodiazepine users have developed protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months.

Potentiation of Sedation from Concomitant Use with Central Nervous System (CNS) Depressants SYMPAZAN has a CNS depressant effect. Caution patients and/or caregivers against simultaneous use with other CNS depressants or alcohol as the effects of other CNS depressants or alcohol may be potentiated.

Somnolence or Sedation SYMPAZAN causes dose-related somnolence and sedation, which generally begins within the first month of treatment and may diminish with continued treatment. Monitor patients for somnolence and sedation, particularly with concomitant use of other CNS depressants. Caution patients against engaging in hazardous activities requiring mental alertness, i.e., operating dangerous machinery or motor vehicles, until the effect of SYMPAZAN is known.

Serious Dermatological Reactions Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with clobazam in both children and adults. Discontinue SYMPAZAN at the fi rst sign of rash, unless the rash is clearly not drug-related.

Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including SYMPAZAN, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

ADVERSE REACTIONS

Adverse reactions (≥10% and more frequently than placebo) included constipation, somnolence or sedation, pyrexia, lethargy, and drooling.

DRUG INTERACTIONS

Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression. Limit dosage and duration of concomitant use of benzodiazepines and opioids and follow patients closely for respiratory depression and sedation.
CNS Depressants and Alcohol: Concomitant use of SYMPAZAN with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence. Caution patients and/or caregivers against simultaneous use with other CNS depressants or alcohol, as effects of other CNS depressants or alcohol may be potentiated.
Hormonal Contraceptives: Hormonal contraceptives that are metabolized by CYP3A4: Effectiveness may be diminished when given with SYMPAZAN. Additional non-hormonal forms of contraception are recommended when using SYMPAZAN.
Drug Metabolized by CYP2D6: SYMPAZAN inhibits CYP2D6, therefore dose adjustment may be necessary of drugs metabolized by CYP2D6 when co-administered with SYMPAZAN.
Strong and Moderate Inhibitors of CYP2C19. Dosage adjustment of SYMPAZAN may be necessary when co-administered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole).
Cannabidiol: Coadministration of cannabidiol and SYMPAZAN may increase the risk of SYMPAZAN-related adverse reactions. Consider dose reduction of cannabidiol or SYMPAZAN should this occur.

USE IN SPECIFIC POPULATIONS

Pregnancy: SYMPAZAN may cause fetal harm and should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have taken benzodiazepines during the later stages of pregnancy can develop dependence, withdrawal syndrome and symptoms suggestive of floppy infant syndrome. Encourage patients to call the toll-free number 1-888-233-2334 to enroll in the Pregnancy Registry or visit http://www.aedpregnancyregistry.org/

Lactation: SYMPAZAN is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from SYMPAZAN, discontinue nursing or discontinue the drug.

Please see Full Prescribing Information, including BOXED WARNING and Patient Information at

https://www.sympazan.com/pdfs/pi.pdf

To report SUSPECTED ADVERSE REACTIONS, contact Assertio Therapeutics at
1-800-518-1084
or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Forward Looking Statements

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio, including our ability to realize the benefits from our operating model, successfully acquire and integrate new assets including Sympazan and explore new business development initiatives. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” “believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may”, “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio, including the risks described in Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.

Investor Contact

Matt Kreps
Managing Director
Darrow Associates
Austin, TX
M: 214-597-8200
[email protected]

CHICAGO, April 24, 2023 (GLOBE NEWSWIRE) — Social media professionals and marketing executives increasingly face pressure to deliver transformative business results while keeping up with the latest industry trends and news. To empower them to navigate these challenges and create a larger impact across their organizations, Sprout Social, an industry-leading provider of cloud-based social media management software, today announced the launch of The Arboretum, a community platform for social and marketing professionals to connect with peers, learn new skills, and exchange actionable advice.

The community is open to all marketers at no cost. Members have access to networking and educational opportunities, and the ability to connect with like-minded peers—from practitioners to C-suite executives. Members will also have access to exclusive events featuring a variety of keynote speakers from leading brands, peer discussions on current trends in content and social strategy, and advice on best practices for achieving their goals.

“Mentorship has been one of the most valuable resources in advancing my career, and the impact of having access to a community of industry experts cannot be understated,” said Jamie Gilpin, CMO, Sprout Social. “Our collective knowledge is a powerful asset that will help marketers across the globe inform org-wide business strategies while leveling up their skills and careers. We’re excited to see how the community will turn shared insights into action.”

Sprout customers who join The Arboretum will receive benefits including previews of product and feature releases and the ability to submit product ideas and feedback directly to the Sprout product team. Whether members are Sprout customers or not, everyone who joins will benefit from rewards and recognition, the ability to source potential candidates or find career opportunities, and more.

“My community managers and I have been able to connect with other social media professionals across a wide variety of different industries to ask questions and have a safe space to share frustrations, or ask for help,” said current member Amanda Scriver, Associate Manager, Community Engagement, Klick. “Every month there are lots of news updates and events that provide a pulse check on trends in the industry, which help my community managers and I stay up-to-date and adapt our strategies accordingly. Overall, the Arboretum is an excellent community to network with peers, learn from experts, and stay ahead of the curve.”

For more information on The Arboretum, please visit community.sproutsocial.com, and learn more about Sprout Social at sproutsocial.com.

About Sprout Social


Sprout Social
is a global leader in social media management and analytics software. Sprout’s unified platform puts powerful social data into the hands of more than 34,000 brands so they can make strategic decisions that drive business growth and innovation. With a full suite of social media management solutions, Sprout offers comprehensive publishing and engagement functionality, customer care, connected workflows and AI-powered business intelligence. Sprout’s award-winning software operates across all major social media networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Social Media Profiles:


www.twitter.com/SproutSocial



www.twitter.com/SproutSocialIR



www.facebook.com/SproutSocialInc



www.linkedin.com/company/sprout-social-inc-/



www.instagram.com/sproutsocial



www.tiktok.com/@sproutsocial

Contact:

Media:
Kaitlyn Gronek
Email: [email protected]
Phone: (773) 904-9674

Investors:
Jason Rechel
Twitter: @SproutSocialIR
Email: [email protected]
Phone: (312) 528-9166

FREDERICK, Md., April 24, 2023 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the addition of four independent manufacturing representatives and distributors to its expanding national and global network. Included in the additions are JANZ Corporation, New England Scientific Associates (NESA) by Baker, Crow Food Safety (Pty) Ltd, and ARES Scientific.

The newly added partners bring a wealth of experience and expertise in government, life sciences, and food safety markets located in the United States and South Africa. TOMI has begun to deliver on new contracts, with multiple orders placed in the first quarter of 2023. The SteraMist inventory from these orders will enable our new partners to improve supply chain and operational efficacy by directly delivering SteraMist products to their customers.

U.S.-based medical supplier and distributor, JANZ Corporation, holds government contracts to provide medical and healthcare products to the Department of Homeland Security, Defense Logistics Agency, and Department of Defense. This collaboration presents an opportunity for TOMI to expand its reach into the government sector as a trusted provider of disinfection solutions.

TOMI also welcomes New England Scientific Associates (NESA) by Baker as a new independent manufacturing representative. NESA by Baker represents leading manufacturers of biotechnology and research equipment. With NESA’s expertise and established infrastructure, SteraMist is well-positioned to achieve success in TOMI’s new turnkey integration projects, which involves integrating SteraMist into cage washers, decontamination chambers, and other related equipment.

Globally, TOMI has joined forces with Crow Food Safety (Pty) Ltd, also trading as Crow Environmental Solutions. The company is a life science and medical industry distributor and a preferred supplier of food safety and hygiene products in South Africa and Sub-Saharan Africa, representing TOMI’s first venture in this region, while furthering expansion in the food safety industry on a global scale.

In a strategic move to further its reach in the life sciences industry, TOMI’s manufacturing representative, ARES Scientific, has evolved its service model and is now a new distributor of TOMI products. With a track record of successfully selling SteraMist, ARES Scientific has earned a reputation as a reliable and innovative provider of cutting-edge products for vivarium and life science facilities. The new role of ARES as a SteraMist distributor opens growth opportunities for TOMI in the life science market.

“We are thrilled to welcome JANZ Corporation, NESA, and Crow Environmental to the TOMI network, and we are delighted to announce the new role of ARES Scientific as a TOMI distributor. These new partnerships are an excellent start to 2023, and represent a significant step forward for TOMI, a world leader in disinfection technology,” said E.J. Shane, COO of TOMI. “Each partnership was carefully chosen, with each known for their proven track record of success and expertise in their respective industries. As we move forward through 2023, we continue to maintain discussions with multiple potential SteraMist distributors and manufacturing representatives on a global scale as part of our aggressive strategy to expand and enhance our brand and sales in relevant markets.”

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®  

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.

For additional information, please visit http://www.tomimist.com/ or contact us at [email protected].

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995  

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to anticipated financial performance and operating results, including expected growth in sales and market demand; anticipated performance of strategic partnerships; anticipated revenue opportunities of CES products; growth strategies of the company; and anticipated distribution capability.

Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:  

John Nesbett/Jennifer Belodeau  

IMS Investor Relations  

[email protected]

Management to host conference call and webcast at 4:30 pm ET on that day

Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Wednesday, May 3, 2023 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023 and to provide a corporate update.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.

Date: May 3, 2023
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-844-826-3035
Participant Dial-in (international): 1-412-317-5195
Conference ID: 10177985

A live audio webcast of the call can be accessed using this link or by clicking here:

https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNQ==

A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through May 10 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 10177985.

About INmune Bio, Inc.

INmune

 

Bio,

 

Inc

.
 is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO (858) 964-3720
[email protected]

Investor Contact:
Jason Nelson
Core IR
(516) 842-9614 x-823

PALO ALTO, Calif., April 24, 2023 (GLOBE NEWSWIRE) — Intapp, Inc., (Nasdaq: INTA), a leading provider of cloud software for the global professional and financial services industry, will report fiscal third quarter 2023 financial results after the market close on May 8, 2023. On that day, management will host a webcast at 5 p.m. ET to discuss the company’s business and financial results.

Investors and other interested parties can access the webcast as follows:

What: Intapp fiscal third quarter 2023 earnings webcast

When: Monday, May 8, 2023

Time: 5 p.m. ET

Live webcast: Investors | Intapp, Inc.

Replay: An archived webcast of the event will be accessible from the “news and events” section of the company’s investor relations website at Investors | Intapp, Inc. The replay will be available for 90 days following the live presentation.

About Intapp

Intapp makes the connected firm possible. We provide cloud software solutions that address the unique operating challenges and regulatory requirements of the global professional and financial services industry. Our solutions help more than 2,200 of the world’s premier private capital, investment banking, legal, accounting, and consulting firms connect their most important assets: people, processes, and data. As part of a connected firm, professionals gain easy access to the information they need to win more business, increase investment returns, streamline deal and engagement execution, and strengthen risk management and compliance.

Investor contact 

David Trone
Senior Vice President, Investor Relations
Intapp, Inc.
[email protected]

Media contact

Ali Robinson
Global Media Relations Director
Intapp, Inc.
[email protected]